

# Partnerships, Licensing, Investments Pharmaceuticals Market Outlook 2017

*Partnerships, Licensing, Investments Pharmaceuticals market forecast*

PUNE, INDIA, September 15, 2017 /EINPresswire.com/ -- Pune, India, 15th September 2017: WiseGuyReports announced addition of new report, titled "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2017".

## Summary

"Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2017", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q2 2017. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/2260440-partnerships-licensing-investments-and-m-a-deals-and-trends-in-pharmaceuticals>

The pharmaceutical and healthcare industry reported a decrease in the number of deals and deal values in Q2 2017 with 1,110 deals worth USD91.3 billion, as compared 1,224 worth USD163.8 billion in Q2 2016. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q2 2017, when compared to 1,185 deals worth USD95.9 billion in Q1 2017. The pharmaceutical and healthcare industry reported a decrease in upfront payments in licensing agreements with USD725.3m in Q2 2017, as compared USD1.1 billion in Q2 2016. On a quarter-on-quarter basis, the upfront payments reported a marginal increase in Q2 2017, when compared to USD723.6m in Q1 2017. Deals in oncology therapeutics market registered a decrease with 374 deals in Q2 2017, compared to 434 deals in Q1 2017. North America reported a decrease in the number of deals from 798 in Q1 2017 to 696 in Q2 2017.

## Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

#### Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

#### Table of Content: Key Points

1	Table of Contents	2
1.1	List of Tables	5
1.2	List of Figures	7
2	Pharmaceuticals & Healthcare, Global, Deal Summary, Q2 2017	10
2.1	Pharmaceuticals & Healthcare, Global, Deals Analysis, Q2 2017	10
2.2	Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q2 2017	12
2.3	Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q2 2017	13
2.4	Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2017	14
2.4.1	Becton, Dickinson to Raise USD10.5 Billion in Public Offering of Notes	14
2.4.2	INC Research and inVentiv Health to Merge	14
2.4.3	Thermo Fisher Scientific to Acquire Patheon	15
2.4.4	Pamplona Capital Management to Acquire Parexel International for USD5 Billion	15
2.4.5	Fresenius to Acquire Akorn	16
3	Pharmaceuticals & Healthcare, Global, Deals Summary, by Type	17
3.1	Pharmaceuticals & Healthcare, Global, M&A, Q2 2017	17
3.1.1	Top M&A Deals in Q2 2017	18
3.1.2	Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q2 2016 - Q2 2017	19
3.2	Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q2 2017	20
3.2.1	Top Initial Public Offerings in Q2 2017	21
3.2.2	Top Secondary Offerings in Q2 2017	21
3.2.3	Top PIPE Deals in Q2 2017	22
3.2.4	Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q2 2016 - Q2 2017	22
3.3	Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q2 2017	24
3.3.1	Top Venture Financing Deals in Q2 2017	25

- 3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2017 25
- 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2017 26
- 3.3.5 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q2 2016 - Q2 2017 27
- 3.3.6 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q2 2016 - Q2 2017 28
- 3.3.7 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q2 2016 - Q2 2017 29
- 3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q2 2017 30
- 3.4.1 Top Private Equity Deals in Q2 2017 31
- 3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals,

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.